Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
50
PLX Quote, Financials, Valuation and Earnings
Last price:
$2.06
Seasonality move
:
9.71%
Day range:
$1.99 - $2.11
52-week range:
$1.32 - $3.10
Dividend yield:
0%
P/E ratio:
28.78x
P/S ratio:
2.54x
P/B ratio:
3.04x
Volume:
3.8M
Avg. volume:
713.1K
1-year change:
-8.81%
Market cap:
$160.8M
Revenue:
$53.4M
EPS (TTM):
$0.07
Analysts' Opinion
-
Consensus RatingProtalix Biotherapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.00, Protalix Biotherapeutics, Inc. has an estimated upside of 450% from its current price of $2.07.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $2.07.
Fair Value
-
According to the consensus of 1 analyst, Protalix Biotherapeutics, Inc. has 450% upside to fair value with a price target of $11.00 per share.
PLX vs. S&P 500
-
Over the past 5 trading days, Protalix Biotherapeutics, Inc. has overperformed the S&P 500 by 10.1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Protalix Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Protalix Biotherapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Protalix Biotherapeutics, Inc. reported revenues of $17.9M.
Earnings Growth
-
Protalix Biotherapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Protalix Biotherapeutics, Inc. reported earnings per share of $0.03.
Enterprise value:
139.6M
EV / Invested capital:
--
Price / LTM sales:
2.54x
EV / EBIT:
21.93x
EV / Revenue:
2.26x
PEG ratio (5yr expected):
0.14x
EV / Free cash flow:
-11.94x
Price / Operating cash flow:
19.31x
Enterprise value / EBITDA:
17.95x
Gross Profit (TTM):
$35.6M
Return On Assets:
7.3%
Net Income Margin (TTM):
8.72%
Return On Equity:
12.06%
Return On Invested Capital:
10.63%
Operating Margin:
11.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $63.6M | $45.7M | $61.8M | $18M | $17.9M | |
| Gross Profit | $47.1M | $16.4M | $35.6M | $9.6M | $9.5M | |
| Operating Income | $13.6M | -$8.9M | $6.4M | $4M | $2.1M | |
| EBITDA | $14.7M | -$7.6M | $7.8M | $4.3M | $2.5M | |
| Diluted EPS | $0.04 | -$0.14 | $0.07 | $0.03 | $0.03 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $71.2M | $45.8M | $72.6M | $47.9M | $66.5M | |
| Total Assets | $83.5M | $56.7M | $87.6M | $61.6M | $82.3M | |
| Current Liabilities | $42.8M | $34.3M | $43.4M | $24.2M | $21.9M | |
| Total Liabilities | $83.3M | $68.2M | $49.3M | $29.1M | $29.4M | |
| Total Equity | $213K | -$11.5M | $38.2M | $32.4M | $52.9M | |
| Total Debt | $36.7M | $32.1M | $24.7M | $4.2M | $6.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.5M | $8.3M | -$10M | $4.1M | -$3.7M | |
| Cash From Investing | -$11.4M | $19.2M | -$16.6M | $20.3M | -$504K | |
| Cash From Financing | $28.7M | -$20.4M | $12.8M | -$20.4M | -- | |
| Free Cash Flow | -$8.6M | $7.2M | -$11.7M | $4M | -$4.2M | |
PLX
Sector
Market Cap
$160.8M
$28.3M
Price % of 52-Week High
64.52%
51.99%
Dividend Yield
0%
0%
Shareholder Yield
-5.16%
-1.59%
1-Year Price Total Return
-11.89%
-17.41%
Beta (5-Year)
-0.251
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.84
200-day SMA
Buy
Level
$1.92
Bollinger Bands (100)
Buy
Level
1.66 - 2.24
Chaikin Money Flow
Buy
Level
1.7M
20-day SMA
Buy
Level
$1.81
Relative Strength Index (RSI14)
Buy
Level
65.92
ADX Line
Buy
Level
25.38
Williams %R
Sell
Level
-17.6471
50-day SMA
Buy
Level
$1.91
MACD (12, 26)
Buy
Level
0.45
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
3.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.9165)
Buy
CA Score
(Annual)
Level (-0.0383)
Buy
Beneish M-Score
(Annual)
Level (-3.0944)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (1.0899)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
Stock Forecast FAQ
In the current month, PLX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PLX average analyst price target in the past 3 months is $11.00.
-
Where Will Protalix Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Protalix Biotherapeutics, Inc. share price will rise to $11.00 per share over the next 12 months.
-
What Do Analysts Say About Protalix Biotherapeutics, Inc.?
Analysts are divided on their view about Protalix Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Protalix Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Protalix Biotherapeutics, Inc.'s Price Target?
The price target for Protalix Biotherapeutics, Inc. over the next 1-year time period is forecast to be $11.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PLX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Protalix Biotherapeutics, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of PLX?
You can purchase shares of Protalix Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Protalix Biotherapeutics, Inc. shares.
-
What Is The Protalix Biotherapeutics, Inc. Share Price Today?
Protalix Biotherapeutics, Inc. was last trading at $2.06 per share. This represents the most recent stock quote for Protalix Biotherapeutics, Inc.. Yesterday, Protalix Biotherapeutics, Inc. closed at $2.07 per share.
-
How To Buy Protalix Biotherapeutics, Inc. Stock Online?
In order to purchase Protalix Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PLX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PLX
Sector
P/E ratio
28.78x
24.24x
PEG ratio
0.14x
-0.01x
P/B ratio
3.04x
1.84x
Price / LTM sales
2.54x
1.60x
Growth Metrics
PLX
Sector
Revenue growth
-0.6%
4.6%
Earnings growth
-13.39%
10.71%
Revenue (5-year growth)
-0.48%
6.45%
Earnings forecast
--
-$0.19
Profitability
PLX
Sector
Profitability FY 2024
$29.1M
$3.5M
Return on invested capital
10.63%
-32.04%
Return on assets
7.3%
-28.44%
Return on equity
12.06%
-38.09%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Feb
12
Balance Sheet
PLX
Sector
Total cash
$29.4M
$26.1M
Short term investments
$15.1M
$25.7M
Total assets
$73.4M
$76.4M
Long term debt
$6.8M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
